-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, LYUx2eetvIKGih4DTAa+Bp/VMw7FRw2nRTgpjXx9azWArElB4njyTyF7PtV4zTcr UMXjg2mm4bc3wa5k77bewg== 0001193125-10-030708.txt : 20100212 0001193125-10-030708.hdr.sgml : 20100212 20100212165839 ACCESSION NUMBER: 0001193125-10-030708 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20100212 DATE AS OF CHANGE: 20100212 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: SUNESIS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001061027 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943295878 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-81034 FILM NUMBER: 10600599 BUSINESS ADDRESS: STREET 1: 395 OYSTER POINT BOULEVARD STREET 2: SUITE 400 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-266-3500 MAIL ADDRESS: STREET 1: 395 OYSTER POINT BOULEVARD STREET 2: SUITE 400 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: MOSAIC PHARMACEUTICALS INC DATE OF NAME CHANGE: 19980709 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BRISTOL MYERS SQUIBB CO CENTRAL INDEX KEY: 0000014272 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 220790350 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: 345 PARK AVE CITY: NEW YORK STATE: NY ZIP: 10154 BUSINESS PHONE: 2125464000 MAIL ADDRESS: STREET 1: 345 PARK AVE CITY: NEW YORK STATE: NY ZIP: 10154 FORMER COMPANY: FORMER CONFORMED NAME: BRISTOL MYERS CO DATE OF NAME CHANGE: 19891012 SC 13G/A 1 dsc13ga.htm SCHEDULE 13G AMENDMENT NO. 1 Schedule 13G Amendment No. 1

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 13G

(Amendment No. 1)*

Under the Securities Exchange Act of 1934

 

 

Sunesis Pharmaceuticals, Inc.

(Name of issuer)

 

 

Common Stock

(Title of class of securities)

867328 50 2

(CUSIP number)

February 12, 2010

(Date of event which requires filing of this statement)

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

¨ Rule 13d-1(b)

x Rule 13d-1(c)

¨ Rule 13d-1(d)

 

*   The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

CUSIP No. 867328 50 2    13G    Page 2 of 5

 

  1   

Name of reporting persons.

I.R.S. Identification Nos. of above persons (entities only).

 

Bristol-Myers Squibb Company

22-0790350

  2  

Check the appropriate box if a member of a group*

(a)  ¨        (b)  ¨

 

  3  

SEC use only

 

  4  

Citizenship or place of organization

 

    Delaware

Number of

shares

beneficially

owned by

each

reporting

person

with

    5    

Sole voting power

 

    1,283,134

   6   

Shared voting power

 

    0

   7   

Sole dispositive power

 

    1,283,134

   8   

Shared dispositive power

 

    0

  9

  

Aggregate amount beneficially owned by each reporting person

 

    1,283,134

10

  

Check if the aggregate amount in Row (9) excludes certain shares (see instructions)*  ¨

 

11

  

Percent of class represented by amount in Row (9)

 

    3.7%

12

  

Type of reporting person*

 

    CO

 

CUSIP No. 867328 50 2    13G    Page 3 of 5

 

Item 1.  

(a)

    Name of issuer:      
     Sunesis Pharmaceuticals, Inc.      
 

(b)

    Address of Issuer’s Principal Executive Offices:      
    

395 Oyster Point Boulevard, Suite 400

South San Francisco, CA 94080

      
Item 2.  

(a)

    Name of person filing:      
     Bristol-Myers Squibb Company      
 

(b)

    Address of Principal Business Office or, if None, Residence:      
    

345 Park Avenue

New York, New York 10154

      
 

(c)

    Citizenship:      
     Delaware      
 

(d)

    Title of Class of Securities:      
     Common Stock      
 

(e)

    CUSIP Number:      
     867328 50 2      
Item 3.   If this statement is filed pursuant to §§240.13d or 240.13d-2(b) or (c), check whether the person filing is a:   
  (a)    ¨    Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
  (b)    ¨    Bank as defined in Section 3(a) (6) of the Act (15 U.S.C. 78c).
  (c)    ¨    Insurance company as defined in Section 3(a) (19) of the Act (15 U.S.C. 78c).
  (d)    ¨    Investment company registered under Section 8 of the Investment Company Act (15 U.S.C. 80a-8).
  (e)    ¨    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).
  (f)    ¨    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).
  (g)    ¨    A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G).
  (h)    ¨    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
  (i)    ¨    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).
  (j)    ¨    Group, in accordance with §240.13d-1(b)(1)(ii)(J).

CUSIP No. 867328 50 2    13G    Page 4 of 5

 

Item 4.    Ownership.      
   (a)    Amount beneficially owned:      
      1,283,134      
   (b)    Percent of class:      
      3.7%      
   (c)    Number of shares as to which the person has:      
      (i)    Sole power to vote or to direct the vote:      
         1,283,134      
      (ii)    Shared power to vote or to direct the vote:      
         0      
      (iii)    Sole power to dispose or to direct the disposition of:      
         1,283,134      
      (iv)    Shared power to dispose or to direct the disposition of:      
         0      
Instruction. For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).
Item 5.    Ownership of Five Percent or Less of a Class.   
   If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following  x   
Item 6.    Ownership of More than Five Percent on Behalf of Another Person.      
   Not applicable.      
Item 7.    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
   Not applicable.
Item 8.    Identification and Classification of Members of the Group.      
   Not applicable.      
Item 9.    Notice of Dissolution of Group.      
   Not applicable.      
Item 10.    Certifications.      
   By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.      

CUSIP No. 867328 50 2    13G    Page 5 of 5

 

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 12, 2010

 

BRISTOL-MYERS SQUIBB COMPANY
By:  

/S/    SANDRA LEUNG        

Name:   Sandra Leung
Title:   Senior Vice President, General Counsel and Corporate Secretary
 -----END PRIVACY-ENHANCED MESSAGE-----